910656-27-8

Basic information

• Product Name: 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one
• Synonyms: MK-0633;4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one;4-(4-fluorophenyl)-7-[[[5-[(2S)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-1,3,4-oxadiazol-2-yl]amino]methyl]chromen-2-one
• CAS NO: 910656-27-8
• Molecular Formula: C₂₂H₁₇F₄N₃O₄
• Molecular Weight: 463.38
• Mol File: 910656-27-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.478
• CAS DataBase Reference: 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one(910656-27-8)
• EPA Substance Registry System: 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one(910656-27-8)

Safety Data

• Hazardous Substances Data: 910656-27-8(Hazardous Substances Data)

Usage

Description

4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one is a complex chemical compound that features a benzopyran-2-one ring, a fluorophenyl group, and an oxadiazol-2-ylamine side chain. It also includes a hydroxy-1-(trifluoromethyl)propyl group attached to the oxadiazol-2-yl group. 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one may possess potential pharmaceutical or biological activity due to the presence of several functional groups commonly found in pharmaceuticals. Further research and analysis are required to ascertain its specific properties and possible applications.

Uses

Used in Pharmaceutical Industry:
4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one is used as a potential pharmaceutical agent for its possible biological activity. The presence of various functional groups suggests that it may have applications in the development of new drugs or therapeutic agents.
Used in Research and Development:
In the field of chemical research and development, 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one serves as a subject for further investigation. Its complex structure and potential biological activity make it an interesting candidate for studies aimed at understanding its properties and exploring its potential uses in various applications.

Upstream product

• 1229617-81-5 C₂₂H₁₉F₄N₃O₄S 
• 910656-32-5 4-(4-fluorophenyl)-2-oxo-2H-chromene-7-carboxaldehyde 
• 1222175-45-2 (2S)-2-(5-amino-1,3,4-oxadiazol-2-yl)-1,1,1-trifluorobutan-2-ol 

Downstream Products

• 1137737-86-0 (S)-4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl}amino)-methyl]-2H-chromen-2-one benzenesulfonate 
• 1137737-87-1 (1S)-N-([4-(4-fluorophenyl)-2-oxo-2H-chromen-7-yl]methyl)-5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-aminium4-methylbenzenesulfonate 

Relevant articles and documents

A practical synthesis of 5-lipoxygenase inhibitor MK-0633

Practical, chromatography-free syntheses of 5-lipoxygenase inhibitor MK-0633 p-toluenesulfonate (1) are described. The first route used an asymmetric zincate addition to ethyl 2,2,2-trifluoropyruvate followed by 1,3,4-oxadiazole formation and reductive amination as key steps. An improved second route features an inexpensive diastereomeric salt resolution of vinyl hydroxy-acid 22 followed by a robust end-game featuring a through-process hydrazide acylation/1,3,4-oxadiazole ring closure/salt formation sequence to afford MK-0633 p-toluenesulfonate (1).

THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR

The instant invention provides compounds of Formula (Ia) which are leukotriene biosynthesis inhibitors, wherein X is O or S, Y is O, S, -NR6-CHR7- or -NR8-C(O)- and A is selected from 5-membered aromatic heterocyclic ring, 6-membered aromatic heterocyclic ring, naphthelenic or heterobicyclic aromatic ring system, phenyl and benzyl. A is optionally mono- or disubstituted. Compounds of Formula (Ia) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.